Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption

Chemico-Biological Interactions

Volumn 256, Issue , 2016, Pages 266-273

  Lee, Suyeon ^a   Ku, Sae Kwang ^b   Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

^b Daegu Haany University   (South Korea)

Author keywords

Barrier integrity; Dabrafenib; Inflammation; Polyphosphate

Indexed keywords

DABRAFENIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYPHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ANTIINFLAMMATORY AGENT; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG REPOSITIONING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY INJURY; LETHALITY; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LIVER INJURY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; SEPSIS; SINGLE DRUG DOSE; SURVIVAL RATE; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANIMAL; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL MOTION; CHEMICALLY INDUCED; DRUG EFFECTS; ENDOTHELIUM CELL; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CAPILLARY PERMEABILITY; CELL MOVEMENT; DRUG REPOSITIONING; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; INFLAMMATION; INTERLEUKIN-4; INTERLEUKIN-6; LEUKOCYTES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NF-KAPPA B; OXIMES; POLYPHOSPHATES; PROTEIN KINASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES;

EID: 84979598508     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2016.07.024     Document Type: Article

References (55)

1. [1] Baek, M.C., Jung, B., Kang, H., Lee, H.S., Bae, J.S., Novel insight into drug repositioning: methylthiouracil as a case in point. Pharmacol. Res. 99 (2015), 185–193.
2. [2] Padhy, B.M., Gupta, Y.K., Drug repositioning: re-investigating existing drugs for new therapeutic indications. J. Postgrad. Med. 57:2 (2011), 153–160.
3. [3] Medina-Franco, J.L., Giulianotti, M.A., Welmaker, G.S., Houghten, R.A., Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov. Today 18:9–10 (2013), 495–501.
4. [4] Ashburn, T.T., Thor, K.B., Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3 (2004), 673–683.
5. [5] Langedijk, J., Mantel-Teeuwisse, A.K., Slijkerman, D.S., Schutjens, M.H., Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov. Today, 2015, 10.1016/j.drudis.2015.1005.1001.
6. [6] Shim, J.S., Liu, J.O., Recent advances in drug repositioning for the discovery of new anticancer drugs. Int. J. Biol. Sci. 10:7 (2014), 654–663.
7. [7] Kumble, K.D., Kornberg, A., Inorganic polyphosphate in mammalian cells and tissues. J. Biol. Chem. 270:11 (1995), 5818–5822.
8. [8] Kulaev, I.S., Vagabov, V.M., Polyphosphate metabolism in micro-organisms. Adv. Microb. Physiol. 24 (1983), 83–171.
9. [9] Shiba, T., Nishimura, D., Kawazoe, Y., Onodera, Y., Tsutsumi, K., Nakamura, R., Ohshiro, M., Modulation of mitogenic activity of fibroblast growth factors by inorganic polyphosphate. J. Biol. Chem. 278:29 (2003), 26788–26792.
10. [10] Hernandez-Ruiz, L., Gonzalez-Garcia, I., Castro, C., Brieva, J.A., Ruiz, F.A., Inorganic polyphosphate and specific induction of apoptosis in human plasma cells. Haematologica 91:9 (2006), 1180–1186.
11. [11] Muller, F., Mutch, N.J., Schenk, W.A., Smith, S.A., Esterl, L., Spronk, H.M., Schmidbauer, S., Gahl, W.A., Morrissey, J.H., Renne, T., Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139:6 (2009), 1143–1156.
12. [12] Bae, J.S., Lee, W., Rezaie, A.R., Polyphosphate elicits pro-inflammatory responses that are counteracted by activated protein C in both cellular and animal models. J. Thromb. Haemost. 10:6 (2012), 1145–1151.
13. [13] Ku, S.K., Bae, J.S., Concentration dependent anti-inflammatory effects thrombin on polyphosphate-mediated inflammatory responses in vitro and in vivo. Inflamm. Res. 62:6 (2013), 609–616.
14. [14] Lee, I.C., Bae, J.S., Anti-inflammatory effects of vicenin-2 and scolymoside on polyphosphate-mediated vascular inflammatory responses. Inflamm. Res. 65:3 (2016), 203–212.
15. [15] Li, J.X., Feng, J.M., Wang, Y., Li, X.H., Chen, X.X., Su, Y., Shen, Y.Y., Chen, Y., Xiong, B., Yang, C.H., Ding, J., Miao, Z.H., The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis., 5, 2014, e1278.
16. [16] Bae, J.S., Lee, W., Nam, J.O., Kim, J.E., Kim, S.W., Kim, I.S., Transforming growth factor beta-induced protein promotes severe vascular inflammatory responses. Am. J. Respir. Crit. Care Med. 189:7 (2014), 779–786.
17. [17] Ku, S.K., Yoon, E.K., Lee, H.G., Han, M.S., Lee, T., Bae, J.S., Inhibitory effects of lysozyme on endothelial protein C receptor shedding in vitro and in vivo. BMB Rep. 48:11 (2015), 624–629.
18. [18] Yoon, E.K., Ku, S.K., Lee, W., Kwak, S., Kang, H., Jung, B., Bae, J.S., Antitcoagulant and antiplatelet activities of scolymoside. BMB Rep. 48:10 (2015), 577–582.
19. [19] Ku, S.K., Lee, W., Kang, M., Bae, J.S., Antithrombotic activities of aspalathin and nothofagin via inhibiting platelet aggregation and FIIa/FXa. Arch. Pharm. Res. 38:6 (2015), 1080–1089.
20. [20] Lee, W., Ku, S.K., Bae, J.S., Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin. Arch. Pharm. Res. 38:5 (2015), 893–903.
21. [21] Hofbauer, R., Moser, D., Salfinger, H., Frass, M., Kapiotis, S., Sufentanil inhibits migration of human leukocytes through human endothelial cell monolayers. Anesth. Analg. 87:5 (1998), 1181–1185.
22. [22] Bae, J.S., Rezaie, A.R., Thrombin inhibits HMGB1-mediated proinflammatory signaling responses when endothelial protein C receptor is occupied by its natural ligand. BMB Rep. 46:11 (2013), 544–549.
23. [23] Bae, J.S., Rezaie, A.R., Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118:14 (2011), 3952–3959.
24. [24] Lee, W., Ku, S.K., Na, D.H., Bae, J.S., Anti-inflammatory effects of lysozyme against HMGB1 in human endothelial cells and in mice. Inflammation 38:5 (2015), 1911–1924.
25. [25] Che, W., Lerner-Marmarosh, N., Huang, Q., Osawa, M., Ohta, S., Yoshizumi, M., Glassman, M., Lee, J.D., Yan, C., Berk, B.C., Abe, J., Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. Circ. Res. 90:11 (2002), 1222–1230.
26. [26] Bae, J.W., Bae, J.S., Barrier protective effects of lycopene in human endothelial cells. Inflamm. Res. 60:8 (2011), 751–758.
27. [27] Kim, T.H., Ku, S.K., Lee, I.C., Bae, J.S., Anti-inflammatory functions of purpurogallin in LPS-activated human endothelial cells. BMB Rep. 45:3 (2012), 200–205.
28. [28] Bae, J.S., Lee, W., Rezaie, A.R., Polyphosphate elicits proinflammatory responses that are counteracted by activated protein C in both cellular and animal models. J. Thromb. Haemost. 10:6 (2012), 1145–1151.
29. [29] Lee, J.D., Huh, J.E., Jeon, G., Yang, H.R., Woo, H.S., Choi, D.Y., Park, D.S., Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. Int. Immunopharmacol. 9:3 (2009), 268–276.
30. [30] Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Metz, C., Miller, E.J., Tracey, K.J., Ulloa, L., Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10:11 (2004), 1216–1221.
31. [31] Rittirsch, D., Huber-Lang, M.S., Flierl, M.A., Ward, P.A., Immunodesign of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 4:1 (2009), 31–36.
32. [32] Diehl, K.H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., Vidal, J.M., van de Vorstenbosch, C., A good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Appl. Toxicol. 21:1 (2001), 15–23.
33. [33] Walton, K.L., Holt, L., Sartor, R.B., Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts through multiple signaling pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 296:3 (2009), G601–G611.
34. [34] Bae, J.S., Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Arch. Pharm. Res. 35:9 (2012), 1511–1523.
35. [35] Schnittler, H.J., Schneider, S.W., Raifer, H., Luo, F., Dieterich, P., Just, I., Aktories, K., Role of actin filaments in endothelial cell-cell adhesion and membrane stability under fluid shear stress. Pflugers Arch. Eur. J. Physiol. 442:5 (2001), 675–687.
36. [36] Friedl, J., Puhlmann, M., Bartlett, D.L., Libutti, S.K., Turner, E.N., Gnant, M.F., Alexander, H.R., Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 100:4 (2002), 1334–1339.
37. [37] Petrache, I., Birukova, A., Ramirez, S.I., Garcia, J.G., Verin, A.D., The role of the microtubules in tumor necrosis factor-alpha-induced endothelial cell permeability. Am. J. Respir. Cell Mol. Biol. 28:5 (2003), 574–581.
38. [38] Komarova, Y.A., Mehta, D., Malik, A.B., Dual regulation of endothelial junctional permeability. Sci. STKE, 2007(412), 2007, re8.
39. [39] Dudek, S.M., Garcia, J.G., Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 91:4 (2001), 1487–1500.
40. [40] Frijns, C.J., Kappelle, L.J., Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 33:8 (2002), 2115–2122.
41. [41] Ulbrich, H., Eriksson, E.E., Lindbom, L., Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol. Sci. 24:12 (2003), 640–647.
42. [42] Javaid, K., Rahman, A., Anwar, K.N., Frey, R.S., Minshall, R.D., Malik, A.B., Tumor necrosis factor-alpha induces early-onset endothelial adhesivity by protein kinase Czeta-dependent activation of intercellular adhesion molecule-1. Circ. Res. 92:10 (2003), 1089–1097.
43. [43] Lockyer, J.M., Colladay, J.S., Alperin-Lea, W.L., Hammond, T., Buda, A.J., Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells. Circ. Res. 82:3 (1998), 314–320.
44. [44] Yamagami, H., Yamagami, S., Inoki, T., Amano, S., Miyata, K., The effects of proinflammatory cytokines on cytokine-chemokine gene expression profiles in the human corneal endothelium. Investig. Ophthalmol. Vis. Sci. 44:2 (2003), 514–520.
45. [45] Marui, N., Offermann, M.K., Swerlick, R., Kunsch, C., Rosen, C.A., Ahmad, M., Alexander, R.W., Medford, R.M., Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J. Clin. Investig. 92:4 (1993), 1866–1874.
46. [46] Rose, B.A., Force, T., Wang, Y., Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol. Rev. 90:4 (2010), 1507–1546.
47. [47] Astiz, M.E., Rackow, E.C., Septic shock. Lancet 351:9114 (1998), 1501–1505.
48. [48] Buras, J.A., Holzmann, B., Sitkovsky, M., Animal models of sepsis: setting the stage. Nat. Rev. Drug Discov. 4:10 (2005), 854–865.
49. [49] Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H.E., Susarla, S.M., Ulloa, L., Wang, H., DiRaimo, R., Czura, C.J., Roth, J., Warren, H.S., Fink, M.P., Fenton, M.J., Andersson, U., Tracey, K.J., Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:1 (2004), 296–301.
50. [50] Dickson, M., Gagnon, J.P., The cost of new drug discovery and development. Discov. Med. 4:22 (2004), 172–179.
51. [51] Liu, X., Zhu, F., Ma, X.H., Shi, Z., Yang, S.Y., Wei, Y.Q., Chen, Y.Z., Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery. Curr. Med. Chem. 20:13 (2013), 1646–1661.
52. [52] O'Connor, K.A., Roth, B.L., Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug Discov. 4:12 (2005), 1005–1014.
53. [53] Tobinick, E.L., The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 22:2 (2009), 119–125.
54. [54] Kaitin, K.I., Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 87:3 (2010), 356–361.
55. [55] Ashburn, T.T., Thor, K.B., Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3:8 (2004), 673–683.